secwatch.observer — SEC 8-K summary
======================================

Issuer:     SOLENO THERAPEUTICS INC (SLNO)
CIK:        0001484565
Form:       8-K
Filed at:   2025-07-11T23:59:59+00:00
Accession:  0001193125-25-157728
Event type: other_material
Sentiment:  neutral
Materiality: 0.85
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Soleno prices $200M public offering of 2.35M shares at $85/share for VYKAT XR commercialization
--------------------------------------------------------------------------------

- Priced 2,352,941 shares at $85.00/share; gross proceeds ~$200M before underwriting discounts.
- Underwriters have 30-day option to purchase up to an additional 352,941 shares at same price.
- Proceeds to fund commercialization of VYKAT XR (diazoxide choline) for Prader-Willi syndrome, approved March 26, 2025.
- Also funds EU regulatory/market development, R&D, and general corporate purposes.
- Offering expected to close July 11, 2025; joint book-runners: Goldman Sachs, Guggenheim, TD Cowen, Cantor, Oppenheimer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1484565/000119312525157728/0001193125-25-157728-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1484565/000119312525157728/d52794d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-157728

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer